The Evolution of Biosimilars from Their Beginning Until Now—And What’s Next
The Inflation Reduction Act Passed, Now What?
What Physicians Want from Pharma—And Where—During Diagnosis and Treatment
Reaching Crucial Hispanic Patient Audiences
5 Ways Your Market Access Strategy Can Create a Better-Connected Patient Experience
Marketing to Type 2 Diabetes Patients: How Pharma Can Increase Treatment Awareness, Improve Outcomes
Trending Now
PM360 Announces Winners of 2022 Trailblazer Awards
NEW YORK, NY, September 23, 2022: PM360, a leading life sciences marketing industry trade ...
The Evolution of Media in Medical Education: Introducing HSS Viewpoint
More than ever, physician time is at a premium. Heavy patient loads, paperwork, research, ...
End-to-End Patient Engagement is the Key to Improving Adherence
Although great strides have been made in the development of new medications for so ...
Transforming Patients’ In-office Experience—And Why it Matters
The point of care is a highly valuable setting for delivering educational health content ...
Measuring the Impact of Telehealth Marketing
In a recent “State of the Point of Care Marketing Industry 2022” report, a ...
The Evolution of Media in Medical Education: Introducing HSS Viewpoint
More than ever, physician time is at a premium. Heavy patient loads, paperwork, research, ...
Rob Califf and the Future of Accelerated Approval
If the regulatory, policy, and political temper tantrums over the FDA’s approval of Exondys ...
The Inflation Reduction Act Passed, Now What?
In April 2022, we released an article describing proposed policies from the federal government ...
Hitting the Sweet Spot: Using Data to Engage Target Audiences
The use of health audience segments is on the rise. Based on campaign data ...
The Evolution of Biosimilars from Their Beginning Until Now—And What’s Next
Chrys Kokino has been involved in the biosimilars market prior to the first biosimilar ...
The Evolution of Biosimilars from Their Beginning Until Now—And What’s Next
Chrys Kokino has been involved in the biosimilars market prior to the first biosimilar ...
